10 Best Healthcare Stocks to Buy According to Billionaires

8. Bristol-Myers Squibb Company (NYSE:BMY)

Number of Billionaire Investors: 17

Value of Billionaire Holdings: $1.9 billion

Bristol-Myers Squibb Company (NYSE:BMY), headquartered in Princeton, New Jersey, develops and distributes biopharmaceutical products globally. The company focuses on areas such as oncology, hematology, immunology, cardiovascular health, and neuroscience. On March 3, Bristol-Myers Squibb announced that its Board of Directors approved a quarterly dividend of $0.62 per share. It is to be paid on May 1, to shareholders on record as of April 4. It ranks 8th on our list of the best healthcare stocks.

In 2024, Bristol-Myers Squibb Company (NYSE:BMY)’s portfolio experienced strong double digit revenue growth, driven by BREYANZI, Krazati, Reblozyl, and Opdivo. The firm prioritized operational efficiency and financial discipline, redirecting resources to high-growth opportunities and achieving most of its targeted $1.5 billion in savings. Fourth quarter sales increased by 9% to approximately $12.3 billion, driven by higher volume and inventory levels. As of December 31, BMY had a solid financial position with around $11.2 billion in cash equivalents and marketable securities, generating $4.4 billion in operating cash flow for the quarter.

On March 14, Bristol-Myers Squibb Company (NYSE:BMY) revealed that the European Commission approved Breyanzi, a CD19-directed CAR T cell therapy, for adults with relapsed or refractory follicular lymphoma who have undergone at least two prior systemic treatments.